Hvis Osigraft genadministreres, kan der derfor være en risiko for udvikling af autoimmunitet mod de endogene BMP- proteiner.
Therefore, upon re- administration of Osigraft, a risk of developing autoimmunity towards the endogenous BMP proteins may exit.